So, we have talked about continued momentum in RFQs. Can you share more perspective on kind of projects a qualitative perspective on RFQs that we are receiving versus kind of projects that we are having in existing Pharma CDMO business?
So, I actually wanted more qualitative perspective on the RFQ that are coming versus existing CDMO projects that we are working on?